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ABSTRACT
Interleukin (IL)-4 plays a critical role in the regulation of immune responses and has been detected at high levels in the tumor
microenvironment of cancer patients where it correlates with the grade of malignancy. The direct effect of IL-4 on cancer cells has
been associated with increased cell survival; however, its role in cancer cell proliferation and related mechanisms is still unclear. Here it was
shown that in a nutrient-depleted environment, IL-4 induces proliferation in prostate cancer PC3 cells. In these cells, under nutrient-depletion
stress, IL-4 activates mitogen-activated protein kinases (MAPKs), including Erk, p38, and JNK. Using MAP-signaling-speciﬁc inhibitors, it
was shown that IL-4-induced proliferation is mediated by JNK activation. In fact, JNK-inhibitor-V (JNKi-V) stunted IL-4-mediated
cell proliferation. Furthermore, it was found that IL-4 induces survivin up-regulation in nutrient-depleted cancer cells. Using survivin-
short-hairpin-RNAs (shRNAs), it was demonstrated that in this milieu survivin expression above a threshold limit is critical to the mechanism
of IL-4-mediated proliferation. In addition, the signiﬁcance of survivin up-regulation in a stressed environment was assessed in prostate
cancer mouse xenografts. It was found that survivin knockdown decreases tumor progression in correlation with cancer cell proliferation.
Furthermore, under nutrient depletion stress, IL -4 could induce proliferation in cancer cells from multiple origins: MDA-MB-231 (breast),
A253 (head and neck), and SKOV-3 (ovarian). Overall, these ﬁndings suggest that in a tumor microenvironment under stress conditions, IL-4
triggers a simultaneous activation of the JNK-pathway and the up-regulation of survivin turning on a cancer proliferation mechanism. J. Cell.
Biochem. 113: 1569–1580, 2012.  2011 Wiley Periodicals, Inc.
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C ancer cell survival, proliferation, and metastasis areinﬂuenced by the cytokines and chemokines of the tumor
microenvironment interacting with cells and regulating complex
signaling pathways. Interleukin-4 (IL-4) is known as a T helper
type 2 (TH2) cytokine because it is produced by TH2 cells, and it
is primarily involved in promoting their differentiation and
proliferation. However, IL-4 is also produced by other cells like
natural killer T cells (NKT), mast cells, basophils, and eosinophils
[Sokol et al., 2008; Yoshimoto et al., 2009; Wu et al., 2011].
Furthermore, increased IL-4 and IL-4R expression has been reported
for several tumor cells including breast, ovarian, colon, lung, and
thyroid.[Kawakami et al., 2002; Todaro et al., 2006; Todaro et al.,
2007; Koller et al., 2010]. The direct effect of IL-4 in cancer cells is a
controversial issue, and examples of both tumorigenic and anti-
tumorigenic effects have been reported. Among anti-tumorigenic
functions are the growth inhibition and induction of apoptosis
[Gooch et al., 1998; Chang et al., 2000; Gooch et al., 2002; Yu et al.,
2004]. However, more recent studies show instead that IL-4 can
promote tumor formation by inhibiting apoptosis and enhancing
proliferation [Prokopchuk et al., 2005; Todaro et al., 2006; Li et al.,
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2008]. These conﬂicting results suggest that IL-4 function may
vary, and a detailed analysis of the IL-4-induced signaling
pathways that lead to tumor progression merits further investiga-
tion.
Survivin is a protein of particular importance to cytokine-
induced signaling pathways that control the survival and
proliferation of cancer cells. Survivin (encoded by BIRC5) is a
member of the inhibitor of apoptosis (IAP) family of proteins that
play an essential role in mitosis [Jeyaprakash et al., 2007]. Wild type
p-53, commonly lost or mutated in many cancers, represses survivin
levels both at the mRNA and protein level, while overexpression of
tumor suppressor PTEN has also been shown to induce survivin
down-regulation in a reaction reversed by re-expression of
recombinant survivin [Mirza et al., 2002; Guha et al., 2009].
Furthermore, a conditional deletion of PTEN in mouse prostate
resulted in increased survivin expression that preceded the epithelial
dysplasia [Guha et al., 2009].
In the tumor microenvironment, individual cells in a tumor exist
in various stages of proliferation, autophagy, and apoptosis and
survivin has been shown to play different but important roles in all
three areas [Altieri, 2008]. We have shown that CCL2, a cytokine that
is highly expressed in the tumor microenvironment, protects
prostate cancer PC3 cells from autophagic death by up-regulating
survivin via the phosphatidylinositol 3-kinase/AKT-dependent
pathway [Roca et al., 2008a]. Here we demonstrate that IL-4
promotes prostate cancer PC3 cell proliferation under nutrient-
depletion stress and investigate the pathways and critical factors
induced by IL-4 that mediate this response. The results presented
here indicate that in a nutrient-depleted-stressed microenviron-
ment, IL-4 activates the Jun N-terminal kinase (JNK) pathway and
up-regulates survivin expression to induce proliferation in prostate
cancer PC3 cells, a mechanism that could also function in other
cancer types.
MATERIALS AND METHODS
CELL LINES
PC3-luciferase prostate cancer cells (designated PC3 for simplicity)
were generated as described [Loberg et al., 2006]. MDA-MB-231
(breast cancer), A253 (head and neck cancer), and SKOV-3 (ovarian
cancer) cell-lines were obtained from ATCC. All cells were
maintained in RPMI-1640 supplemented with 10% fetal bovine
serum (FBS) and 1% Antibiotic-Antimycotic (Invitrogen).
WESTERN BLOT ANALYSIS
Cells were grown to 80%-conﬂuency in appropriate medium. Cells
were synchronized by starvation in serum-free-RPMI for 16 h at
378C. Cells were detached using 0.25mM EDTA, then plated in six-
well-culture plates at a density of 1.5 105 cells/ml and treated
with IL-4 and (or) the inhibitors U0126 (MEK1/2 inhibitor), SB
220025 (p38-inhibitor), and JNK-inhibitor-V (JNKi-V); (EMD/
Calbiochem) at the indicated concentrations. To analyze survivin
expression during cell proliferation, cells were detached and plated
in RPMI (0.5–1% FBS) supplemented with IL-4 (100 ng/ml,
Symansis, 4004C). Protein lysates were collected at designated
time-points and the blots performed as previously [Roca et al.,
2008a].
GENERATION OF STABLE SHORT-HAIRPIN-RNA (shRNA)
CELL LINES
Two independent shRNAs (shS-1 and shS-2; Cat. RHS4430-
98520325 and RHS4430-99140887, respectively; Open Biosystems),
as well as control Empty-Vector (EV) and Scrambled (Scr) sequences,
were packaged into lentiviruses by the University of Michigan
Vector Core. Cell-transfection was performed as previously
described [Roca et al., 2008a]. Stable-transfected cell-lines were
named: PC3EV, PC3Scr, PC3sh-1, and PC3sh2. From the whole
population of PC3sh-1, a sub-population sh1-7 (PC3sh1-7) that
showed the largest decrease in survivin expression was isolated and
used in all experiments. PC3sh2 represents the total population from
shS-2-transfected PC3.
PRIMARY ANTIBODIES
All antibodies used in Western-analyses were obtained from Cell
Signaling: Survivin (Cat. 2808), b-Actin mAb (Cat. 4967L),
Phospho-Akt (Ser473) (Cat. 4058), Phospho-c-Raf (Ser338) (Cat.
9427), Phospho-Mek1/2 (Ser217/221) (Cat. 9154), Phospho-Erk1/2
(Ser217/221) (Cat. 9154), ERK1/2 (Ser217/221) (Cat. 4695),
Phospho-p38 (Thr180/Tyr182) (Cat. 4631), p38 (Cat. 9212),
Phospho-JNK (Thr183/Tyr185) (Cat. 4668), JNK (Cat. 4668),
Phospho-ATF2 (Thr71) (Cat. 9221), Phospho-JUN (Ser63) (Cat.
9252), Phospho-p70S6K (Thr389) (Cat. 9234), LC3B (Cat. 3868).
WST-1 CELL VIABILITY ASSAY
Cell Proliferation Reagent WST-1 (Roche) was used to assess cell
viability and chemosensitivity as described [Roca et al., 2008a]. To
analyze cell proliferation in the presence of IL-4, synchronized-cells
were plated in RPMI (0.5–1% FBS) and allowed to attach for 6 h.
After attachment, cells were stimulated with IL-4 (100 ng/ml) and
(or) treated with the inhibitors (U0126-MEK1/2 inhibitor), SB
220025 (p38-inhibitor) and JNKi-V; (EMD/Calbiochem) at the
indicated concentrations.
IN VIVO BIOLUMINESCENT ANALYSIS OF PROSTATE CANCER
GROWTH AND HISTOLOGY
Bioluminescent imaging of PC3EV, PC3Scr, PC3sh1-7, and PC3sh2 cells
was done as previously described [Loberg et al., 2007]. Once
individual mice reached critical tumor burden (ROI> 1 1010
photons per second), tumors were harvested from the left and right
adrenal glands, ﬁxed, parafﬁn-embedded, and 5-mm sections were
placed on glass slides. Hematoxylin–eosin staining was performed
according to the manufacturer’s instructions (Sigma, Inc., St. Louis,
MO). Identiﬁcation of cell proliferation was accomplished by
labeling with an anti-Ki-67 antibody (HPA001164, Sigma), and
survivin staining was performed using anti-survivin antibody (Cell
Signaling; Cat. 2808).
STATISTICAL ANALYSIS
Average values are presented as the means þ/ SD. The data were
analyzed using repeated measures mixed models of WST-1 ratio to
baseline generated for each cell line separately with an unstructured
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correlation matrix. Fixed covariates in the model included
group, time, second order of time (to account for the shape of
the growth), and each time covariate with group interaction.
Pairwise comparisons using contrasts were generated to test the
growth difference between groups. Additionally, the cross-sectional
comparison at 120 h was made using an ANOVA model. Tumor
growth measures were modeled to test the differences in tumor
growth. All statistical models were performed using SAS 9.2 (SAS
Institute, Cary, NC). Statistical signiﬁcance was determined at a
threshold of 0.05 unless otherwise stated. Bonferroni multiple-
comparisons corrections were made to adjust for multiple-testing
where appropriate.
RESULTS
IL-4 INDUCES PROSTATE CANCER CELL PROLIFERATION IN A
NUTRIENT-DEPLETED ENVIRONMENT
Previous studies have suggested that IL-4 may have both
stimulatory and inhibitory effects on the growth of malignant cells
[Topp et al., 1995; Gooch et al., 1998; Chang et al., 2000; Gooch
et al., 2002; Yu et al., 2004; Prokopchuk et al., 2005]. Here we
investigated the effects of IL-4 on the proliferation of prostate
cancer PC3 cells when subjected to nutrient-deprivation stress. To
analyze this effect, PC3 cells were serum-starved for 16 h, plated in
low serum (0.5% FBS), and stimulated with IL-4. Cells were
trypsinized and counted at 24 h intervals (up to 72 h) using the
trypan-blue exclusion assay. Figure 1A depicts the increase over
time in the live cells counts of IL-4-treated samples relative to
control (untreated) cells. A dose response in proliferation is also
observed as an increase in live cells from 50 to 100 ng/ml of IL-4. In
addition PC3 cell proliferation was assessed by performing theWST-
1 assay at increasing time-points. As shown in Figure 1B, the IL-4-
stimulated cells demonstrated a sustained increase in WST-1 values
(up to 96–120 h) that corresponds to an increase in cell number as
observed in Figure 1A. In contrast, the control cells showed modest
proliferation at the expense of the initial nutrients and FBS (0.5%);
however, as the cells became nutrient-depleted they were unable to
proliferate further. To demonstrate that cells become nutrient-
depleted under these culture conditions, protein samples were
collected at different time-points and analyzed by immunoblotting
using the LC3B antibody. Microtubule-associated protein LC3 is
widely used to monitor autophagy [Mizushima and Yoshimori,
2007; Roca et al., 2008b]. Activation of autophagy involves the
cleavage of LC3-I and its conjugation with phosphatidylethanol-
amine to form LC3-II, a process that is essential to autophagosome
formation. As observed in Figure 1C at 24 h when the medium is
fresh the LC3-I band is observed; however, at a later time (72 h and
beyond) this band is almost undetected as a result of cleavage and
conversion into LC3-II (compare lane 1 with 2–7), which serves as a
good indication of higher autophagosome formation and activation
of autophagy. Therefore, since autophagy is activated in response to
nutrient scarcity, these ﬁndings suggest that these culture
conditions generate a nutrient-depleted stressed environment where
IL-4 is capable of inducing proliferation in the prostate cancer PC3
cells.
JNK-PATHWAY ACTIVATION MEDIATES THE IL-4-INDUCED
PROLIFERATION IN PROSTATE CANCER PC3 CELLS
The crucial role of mitogen-activated protein kinase (MAPK)
signaling in the signal transduction of many mitogenic factors
Fig. 1. IL-4 induces prostate cancer PC3 cell proliferation in a nutrient-
depleted environment. A: To analyze the effect of IL-4 in prostate cancer
proliferation, PC3 cells were serum-starved for 16 h, seeded in 24 well/plates
(3 104 cells/well) in low serum (0.5% FBS), and stimulated with IL-4 at two
different concentrations 50 and 100ng/ml. Triplicate samples from control and
IL-4-treated cells were trypsinized and counted at 24 h intervals (up to 72h)
using the trypan-blue exclusion assay and the automated cell counter (Countess,
Invitrogen). The graph depicts the increase in the live cells counts over time in IL-
4-treated and the control (untreated) cells. B: WST-1 cell proliferation assay.
Cells were synchronized for 16h by serum starvation and plated in 96 wells
(3 103 cells/well) in low serum (0.5% FBS) with or without IL-4 (100ng/ml).
The proliferation curves represent the WST-1 values (average absorbance
(440nm)) of n¼ 10 samples measured at 24h increments up to 96h. C:
Autophagy activation in PC3 cells growing under nutrient-depleted conditions.
Cells were synchronized as described above, seeded in 6 well/plates (2 105 cells/
well) (0.5% FBS) and treated or not with IL-4 (100ng/ml). Protein samples were
collected at the indicated time-points and analyzed by Western Blot using the
LC3B antibody. The immunoblot analysis depicts the autophagosome formation
induced by nutrient-depletion, evidenced by the conversion of LC3-I protein into
LC3-II from 24h (low autophagosome formation, LC3-I is observed) to 72–120h
(high autophagosome formation, LC3-I almost undetectable and higher ratio
LC3-II/LC3-I), which serves as a good indicator of autophagy activation.
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and their up-regulation in human tumors has been abundantly
documented [Lopez-Bergami et al., 2007; Wagner and Nebreda,
2009; Ferte et al., 2010]. To determine if MAP-kinases are involved
in the mechanism of IL-4-induced PC3 proliferation, the activation
of MAPK-pathways by IL-4 was investigated. The cells were plated
in serum-free medium for 16 h, and following IL-4-stimulation,
protein lysates were collected at increasing time-points as indicated
in Figure 2A–C. The cells triggered a signaling-cascade with the
activation of MAPK-pathways, including the extracellular signal-
regulated kinase (ERK)1/2, p38, and JNK. As observed in Figure 2A–
C, IL-4 induced phosphorylation of c-Raf, MEK1/2, ERK1/2, p38,
and JNK, as well as downstream targets of p38 and JNK-signaling:
The transcription factors ATF-2 and JUN, two members of the
activator protein 1 (AP-1) family which are implicated as regulators
of altered gene expression and proliferation in response to
cytokines, growth factors and oncogenic transformations [Davis,
2000; Jochum et al., 2001; Shaulian and Karin, 2002].
Next, using speciﬁc kinase-inhibitors for each signaling pathway,
the role of MAP-kinases in the mechanism of IL-4-induced PC3
proliferation was assessed. The contribution of ERK1/2, p38, and
JNK pathways was analyzed in independent experiments using the
inhibitors U0126 (inhibits MEK1/2 upstream of ERK1/2), SB 220025
and (JNKi-V), respectively. First, even though MEK1/2-ERK1/2-
inhibitor (U0126- 10mM) and p38-inhibitor (SB 220025- 0.5mM)
demonstrated target-speciﬁc inhibition of phosphorylation
(Fig. 3B,D), no effect on the cell proliferation induced by IL-4
was observed in a parallel assay (Fig. 3A,C). In contrast, the JNKi-V
not only suppressed JNK phosphorylation (Fig. 3F), but also
demonstrated a dose-dependent inhibition of the IL-4-mediated
proliferation (blue lines, Fig. 3E) in this nutrient-depleted environ-
ment. This inhibitor further suppressed the basal proliferation
observed in the control cells (red lines, Fig. 3E). Altogether these
ﬁndings suggest that IL-4-induced activation of JNK is a function
crucial to promoting prostate cancer PC3 cell proliferation.
IL-4 INDUCES SURVIVIN UP-REGULATION UNDER
NUTRIENT-DEPLETION STRESS AS A CRITICAL FACTOR
IN THE PC3 PROLIFERATION RESPONSE
The connection between cytokines and survivin has been established
in different cancer cells; for example, it has been reported that
different cytokines, like IL-2, IL-4, and GM-CSF, induce survivin up-
regulation [Faderl et al., 2003; Decker et al., 2010]. Furthermore,
survivin plays an essential role in mitosis and has been connected to
cell proliferation networks [Altieri, 2008]. Recently, it was shown
that CCL2 up-regulates survivin in nutrient-depleted PC3 cells [Roca
et al., 2008a; Roca et al., 2009]. Therefore, it was hypothesized that
IL-4 could also up-regulate survivin under nutrient-depletion stress
as a critical mechanism to induce proliferation, and so the effect of
IL-4 on the regulation of survivin was investigated. PC3 cells were
serum starved for 16 h and plated in serum-free media for a total of
96 h to create a nutrient-depleted environment at later culture-
times. Protein lysates were collected at different times and analyzed
by immunoblotting. As shown in Figure 4A, survivin is up-regulated
in nutrient-depleted cells in response to IL-4 compared to the
untreated controls. In fact, the IL-4-induced survivin up-regulation
becomes signiﬁcant at later time-points (72 96 h; see lanes 7–10
Fig. 4A), when survivin levels drop as a result of nutrient depletion
stress (after 48 h of culture).
Next, the impact of survivin up-regulation on the mechanism of
IL-4-mediated proliferation was further investigated in prostate
cancer cells through the generation of survivin-depleted cells using
shRNAs. Two survivin-speciﬁc shRNAs (shS-1 and shS-2), as well as
two corresponding controls: Empty vector (EV) and scrambled
shRNA (Scr), were packaged into lentivirus and transfected into
luciferase-expressing PC3 cells. Following selection, four stable-
transfected cell lines were generated: PC3EV and PC3Scr correspond-
ing to the control vectors, and PC3sh1-7 and PC3sh2 corresponding to
the survivin-speciﬁc shRNAs: shS-1 and shS-2, respectively. These
cells were further characterized in vitro to evaluate cell proliferation
and the corresponding survivin levels. Both control and knockdown
cells were plated in low serum (1% FBS), and the cell viability was
Fig. 2. IL-4 activates the ERK, p38, and JNK signaling pathways in cancer
cells. Immunoblot analysis of prostate cancer PC3 cells demonstrates the
activation of mitotic-activated protein kinase (MAPK) signaling pathways
in response to stimulation with IL-4 (100 ng/ml). MAPK pathways include the
activation of: A: Extracellular regulated kinases, ERK1/2, and (B) the stress-
activated protein kinases, p38-MAPK and the JUN N-terminal kinase (JNK).
The analysis also reveals the activation of downstream transcription-factors,
JUN and ATF2 (C).
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measured using a WST-1 assay at 24 h intervals. As shown in
Figure 4B, both knockdown and control lines demonstrated similar
proliferation rates during the ﬁrst 72 h. At this time, a parallel
immunoblotting analysis revealed high levels of survivin in all
cells, including the knockdown cells (Fig. 4C). However, after
72 h, PCsh1-7, and PC3sh2 showed a signiﬁcant decrease in cell
proliferation compared to controls (Fig. 4B). As seen in Figure 4C, at
144 h, survivin levels demonstrated a signiﬁcant drop in knockdown
cells (PC3sh1-7 and PC3sh2), which correlates with the nutrient
exhaustion that occurs at a later times and a signiﬁcant decrease in
cell proliferation (Fig. 4B). Altogether, this analysis suggests that
survivin-shRNAs could effectively induce knockdown only under
conditions of limited nutrients. In fact the knockdown-shRNAs have
a limited effect during conditions of abundant nutrients at the initial
culture times (ﬁrst 72 h), when survivin levels are high enough to
sustain proliferation. However, when survivin drops below a critical
threshold (after 72 h), as a result of nutrient-depletion and the effect
of shRNAs, then the cell proliferation declines as observed in
knockdown cells (Fig. 4B).
Following cell characterization, it was investigated how survivin-
knockdown affects the IL-4-mediated proliferation in these cells.
Three cell lines: PC3, PC3Scr (controls), and PC3sh1-7 (knockdown)
were serum starved and plated in 0.5% FBS to create a nutrient-
depleted environment in these cultures and proliferation was
assessed upon IL-4 stimulation. As shown in Figure 5A, IL-4-
stimulated cells showed a major increase in proliferation relative to
control (untreated) cells. However, the IL-4-mediated proliferation
response was considerably lower in knockdown (PC3sh1-7) when
compared to controls. These ﬁndings suggest that the shRNA-
mediated survivin knockdown reduces the proliferation-inducing
Fig. 3. JNK-pathway activation mediates the IL-4-induced proliferation in prostate cancer PC3 cells. IL-4-induced proliferation is JNK-pathway dependent and ERK and p38
independent. Speciﬁc kinase inhibitors were used to analyze the role of MAP-kinases in the IL-4-induced proliferation mechanism. Cell proliferation was assessed byWST-1 dye
conversion at 24 h increments (as described in Fig. 1B; where theWST-1 values represent the average absorbance of n¼ 10 samples per condition) for IL-4 treated and untreated
PC3 in the presence of the following inhibitors: (A) MEK1/2-i (U0126, inhibits MEK1/2 upstream of ERK1/2); (C) p38-i (SB 220025, inhibits p38 activation) and (E) JNKi-V
(JNK-inhibitor-V, inhibits JNK activation). The inhibitors were used at the indicated concentrations. All WST-1 values were normalized to the values at 24 h. The speciﬁcity of
the inhibitors was evaluated by Western blot in each case using phospho-speciﬁc antibodies as indicated in (B) (MEK1/2-i), (D) (p38-i), and (F) (JNKi-V).
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potential of IL-4 on prostate cancer cells. In a parallel assay, survivin
levels were examined at two different time points: 48 and 96 h
(Fig. 5B). The 96 h time-point corresponds to a more advanced
nutrient-depletion stage in culture as compared with 48 h. As shown
in Figure 5B survivin expression was higher in control cells (PC3 and
PC3Scr) as compared to PC3sh1-7. Additionally, IL-4-stimulation
induced a signiﬁcant survivin up-regulation in the knockdown-cells
(compare lanes 5 and 6 and 11 and 12). This increase was more
striking at 96 h (lanes 7–12), when IL-4 was able to rescue the
expression of survivin (compared to control PC3Scr and PC3sh1-7
cells). The rescue of survivin correlates with the increasing slope in
the proliferation curve from 96 to 120 h (Fig. 5A). Furthermore, the
critical drop of survivin, observed in PC3sh1-7 cells from 48 to 96 h
(lanes 5 and 11, Fig. 5B), also correlates with the reduced
proliferation when compared to control cells (PC3 and PC3Scr).
To understand the mechanism of IL-4-induced survivin up-
regulation, by which survivin expression is rescued in PC3sh1-7 cells
(Fig. 5B), the mRNAs were isolated from control and IL-4-treated
cells and the relative survivin-mRNA expression was analyzed. As
shown in Figure 5C no signiﬁcant changes were observed in
survivin-mRNA between control and IL-4-stimulated cells at two
different times: 72 and 96 h. These results suggest that survivin up-
regulation is not controlled by a transcriptional mechanism, but
rather by differences in mRNA translation. Furthermore, in prostate
cancer cells it has previously been shown that hyperactivation of
mTORC1 and the downstream kinase p70S6K originate a differential
survivin expression at the protein level through changes in mRNA-
translation [Vaira et al., 2007; Roca et al., 2009]. In fact, as shown in
Figure 5D, IL-4 induces a sustained activation of p70S6K (lanes 2
and 4), while the activated kinase is dramatically down-regulated in
control cells by 96 h (lanes 2–3). Therefore, these ﬁndings suggest
that IL-4 opposes the negative effect of survivin-shRNA by
stimulating a sustained increase in the translated survivin. In total,
these results are similar to previous reports showing that p70S6K
activation mediates survivin protein up-regulation in prostate
cancer cells by cytokines like CCL2 [Roca et al., 2008a; Roca et al.,
2009] or IGF1 [Vaira et al., 2007].
Subsequently, the possible link between JNK-activation and
survivin up-regulation in the IL-4-induced proliferation mechanism
under nutrient-depletion stress was further assessed using PC3sh1-7
cells. The experiment was performed as described in Figure 3E, and
both control and IL-4-stimulated cells were treated with JNKi-V at
2.5mM, a concentration known to affect cell proliferation. The cells
were incubated for 72 and 96 h, and survivin expression was
analyzed by immunoblotting at these time-points. As expected,
survivin decreased at 96 h with the increase of nutrient scarcity
Fig. 4. IL-4 induces survivin up-regulation in nutrient-depleted PC3 cells. A: Immunodetection showing the time-course effect of IL-4 on survivin expression in nutrient-
depleted prostate cancer cells. PC3 cells were serum starved for 16 h and cultured in serum-free media for a total of 96 h to create a nutrient-depleted environment. Protein
lysates were collected at different time-points and analyzed byWestern blot using survivin monoclonal antibody (Cell Signaling). The ﬁgure depicts the survivin up-regulation in
nutrient-depleted PC3 in response to IL-4 stimulation compared to the untreated controls. Up-regulation of survivin by IL-4 was observed at 72 and 96 h (compare lanes 7 and 8
to 9 and 10). At these later times the nutrient scarcity is intensiﬁed and survivin levels signiﬁcantly drop as a result of nutrient-depletion stress (after 48 h of culture, compare
lanes 1–6 to 7 and 9). B–C: Progression of cell proliferation is dependent on survivin expression above a critical threshold level. Analysis of cell proliferation and survivin protein
in PC3 cells expressing survivin-speciﬁc shRNA (sh1-7 and sh2) as compared to the controls (PC3, Scr (scrambled-shRNA) and EV (empty vector)). B: Cells were cultured in the
presence of low serum (1% FBS) and cell proliferation was evaluated by measuring the WST-1 absorbances at increasing time points up to 196 h (n¼ 10 per cell-line at each
time-point). C: Parallel Western analysis of survivin protein that correspond to 24, 72, and 144 h of the time course. Note that survivin protein levels signiﬁcantly drop in the
knockdown-cells (PC3sh2 and PC3sh1-7) from 72 to 144 h, when the conditions of nutrient scarcity are achieved and the differences in cell proliferation are accentuated
compared to controls (PC3, PC3Scr and PC3EV) (see Fig. 4B).
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(lanes 5–6), and IL-4-stimulation induced survivin up-regulation
in these cells (lanes 7–8); however, survivin expression was not
affected by treatment with a JNK-inhibitor when used at a
concentration that affects cell proliferation (Fig. 5E). Altogether
these ﬁndings suggest that survivin up-regulation is independent of
JNK-activation, and therefore, both survivin up-regulation and
JNK-activation are two essential factors induced by IL-4 to sustain
prostate cancer proliferation under nutrient-depletion stress.
SURVIVIN KNOCKDOWN DECREASES TUMOR PROGRESSION AND
INCREASES MOUSE SURVIVAL IN CORRELATION WITH CANCER
CELL PROLIFERATION UNDER NUTRIENT-DEPLETION STRESS
The signiﬁcance of survivin up-regulation in a nutrient-depleted or
stressed environment was further assessed in vivo. Control and
survivin-knockdown cells were injected into the left ventricle of
male SCID-mice (ICI model) [Arguello et al., 1988; Jenkins et al.,
2003]. Mice were imaged weekly, and the total tumor burden was
analyzed and calculated as regions of interest (ROI). Fifteen mice
were injected per cell line, and survivin-knockdown cells, PC3sh2
and PC3sh1-7 were compared to the controls, PC3EV and PC3Scr.
Analysis of ROI-values revealed signiﬁcant differences in tumor
burden between controls and survivin-knockdown cells (Fig. 6A).
This signiﬁcant delay in tumor progression in the survivin-
knockdown groups correlates with the differences observed in
cell proliferation between these cells and the controls in a nutrient-
depleted environment (Fig. 4B,C). Furthermore, as shown in
Figure 6B, the Kaplan–Meier survival analysis also correlates
with the tumor progression differences observed between the
groups. In fact, mice injected with survivin-knockdown cancer cells
showed a signiﬁcant increase in survival when compared to control
mice (average survival 76% for knockdown-injected mice compared
to 36% for the control mice; P-value <0.05).
Once control mice reached critical tumor burden (ROI> 1 1010),
tumors were dissected from adrenal glands for each group of mice.
Collected samples were stained for hematoxylin and eosin (H&E),
survivin, and Ki67, a known marker of cell proliferation [Whitﬁeld
Fig. 5. IL-4 induces survivin up-regulation under nutrient-depletion stress as a critical factor in the PC3 proliferation response. IL-4-mediated cell proliferation was analyzed
in survivin-depleted cells (PC3-sh1-7) and compared to controls (PC3 and PC3-Scr). A: Cell proliferation was assessed by measuring the WST-1 absorbance at increasing time
points up to 120 h (n¼ 10). B: Parallel analysis by Western blot of survivin expression corresponding to 48 and 96 h of culture. C: Analysis of survivin mRNA in IL-4-treated
PC3sh1-7 compared to untreated cells. The total RNA was isolated from triplicate samples of IL-4-stimulated or control cells at 72 and 96 h of culture. The graph depicts
the ratios of survivin mRNA in IL-4-treated relative to control samples after normalization to the b-Actin control-probe (survivin probe- Hs00977611_g1 and b-Actin-
Hs99999903_m1; TaqMan Gene Expression Assays, Life Technologies). D: In a parallel experiment as described in (C), the protein was also collected and the activation of p70S6
kinase (a downstream target of mTOR Complex-1) was analyzed by immunoblotting using the phospho-speciﬁc antibody (phospho-p70S6K-Thr389). Note a sustained
activation of p70S6 kinase in IL-4 stimulated cells (lanes 2 and 4), while a critical drop is observed at 96 h in control cells. E: Survivin expression is not affected by treatment
with a JNK-inhibitor-V (JNKi-V). The experiment was performed as described in Figure 3E, and both control and IL-4-stimulated cells were treated with JNKi-V at 2.5mM. The
cells were incubated for 72 and 120 h, and survivin expression was analyzed by immunoblotting at these time points.
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et al., 2002; Glinsky et al., 2005]. A representative staining is shown
in Figure 6C. H&E staining revealed similar tumor morphology with
high concentration of cancer cells in all groups (Fig. 6C; panels a1–
a4). However, as expected, the control groups PC3EV and PC3Scr
showed a signiﬁcantly higher survivin staining compared to the
knockdown (Fig. 6C; panels b1–b4). Furthermore, correlating to the
in vitro data, the proliferation marker Ki67 revealed an increased
staining in the controls compared to survivin-knockdown (PC3sh1-7
and PC3sh2) (Fig. 6C; panels c1–c4). Overall, these results indicate
a direct correlation between the survivin levels and tumor-cell-
proliferation, which also correlates with overall tumor progression
and mouse-survival. Therefore, decreasing survivin levels in the
cancer cells results in decreased cancer proliferation in the mouse
microenvironment.
IL-4 INDUCES PROLIFERATION IN CANCER CELLS FROM
DIFFERENT ORIGINS
As IL-4-induced cancer cell proliferation may have implications in
the progression of other types of cancer, its effect was investigated in
cancer cells from different origins: In breast cancer MDA-MB231,
head and neck cancer A253, and ovarian cancer SKOV-3 cells. Using
a similar approach as described for PC3, the effect of IL-4 on cell
proliferation was assessed by performing a WST-1-assay at
increasing time-points in low-serum conditions (0.25–0.5% FBS).
As shown in Figure 7A, the IL-4-stimulated cells demonstrated a
sustained increase in WST-1-values, while the control-cells showed
modest proliferation up to the ﬁrst 48 h of culture, the point when
the cells encounter nutrient-scarcity and are unable to proliferate
further. These results suggest that IL-4 has the potential to induce
proliferation in environmentally stressed cancer cells of different
origins similar as it does with PC3 cells.
Next, MDA-MB-231 cells were selected to investigate if JNK-
pathway activation is essential to this proliferation mechanism.
Similar to PC3, when MDA-MB-231 cells were treated with the
JNKi-V, a dose-dependent inhibition of IL-4-mediated cell
proliferation was achieved (Fig. 7B). These ﬁndings imply that
IL-4-induced activation of JNK-signaling is crucial to promote
cancer proliferation. Furthermore, survivin is also up-regulated by
IL-4 in nutrient-depleted MDA-MB-231 cells (Fig. 7C), suggesting
that both factors identiﬁed to be crucial in the mechanism of IL-4-
induced proliferation in nutrient-depleted PC3, JNK-activation, and
survivin up-regulation (Fig. 7D), could play a critical function in
different cancer types. However, a complete elucidation in each case
requires further investigation.
Fig. 6. Survivin knockdown decreases tumor progression and increases mouse survival in correlation with cancer cell proliferation under nutrient-depletion stress. In vivo
analysis of tumor progression using the ICI model to compare survivin-knockdown and control cells. A: Bioluminescence analysis of tumor growth. The graph depicts the average
tumor burden calculated from regions of interest (ROIs in photons/second) of all mice for every group (EV, Scr, sh1-7, and sh2). B: Kaplan–Meier cancer-survival curves showing
mouse survival for every group. C: Immunohistochemical analysis of adrenal tumor samples from each group of mice stained for hematoxilin and eosin (H&E) (panels a1–a4),
the proliferation marker, Ki67 (panels b1–b4), and survivin (panels c1–c4).
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DISCUSSION
Several studies support the role of IL-4 as a contributor to tumor
progression via its effect on the cells of the tumor microenvironment
[Stremmel et al., 1999; Fukushi et al., 2000; Gordon, 2003; Gocheva
et al., 2010]. For example, IL-4 induces the alternative activation of
macrophages (M2-type) and contributes to the transition of
macrophages into tumor-promoting that facilitate tumor growth,
angiogenesis, and invasion [Mantovani et al., 2008]. Furthermore,
increased levels of IL-4 receptor have been reported in a variety of
human cancers [Kawakami et al., 2002; Koller et al., 2010], and IL-4
may actually promote tumorigenesis by a direct effect on the
malignant cells [Conticello et al., 2004; Todaro et al., 2006; Li et al.,
2008]. Aberrantly increased cell proliferation is a requisite of
successful tumor progression and the ability tometastasize at distant
sites. Although studies have found examples of IL-4 having both
negative and positive effects on cell proliferation in general, studies
with cancer cells have suggested that IL-4 promotes malignant cell
proliferation, though the mechanism is still unclear [Myers et al.,
1996; Prokopchuk et al., 2005]. The results presented here
demonstrate that IL-4 is a potent inducer of prostate cancer PC3
cell proliferation when the cells are subjected to nutrient-depletion
stress (Fig. 1). In fact the autophagy activation at 72 h strongly
suggests that cells are subjected to nutrient-scarcity (Fig. 1C). In
addition, critical factors in this mechanism have been elucidated in
these prostate cancer cells. It was demonstrated that IL-4 activates
three MAPK signaling pathways in these cells: ERK, p38, and JNK
(Fig. 2). Using speciﬁc inhibitors that differentiate between each
pathway, the role of each signaling in cell proliferation was
further assessed. This approach allowed the identiﬁcation of the
Fig. 7. IL-4 induces proliferation in cancer cells from different origins. A: The IL-4 effect on cell proliferation was investigated in the breast cancer MDA-MB231, head and
neck cancer A253, and ovarian cancer SKOV-3 cells. Cells were synchronized for 16 h by serum starvation and then plated in low serum (0.25–0.5% FBS) with or without IL-4
(100ng/ml). The proliferation curves represent the WST-1 values (average absorbance (440 nm)) of n¼ 10 samples for each cell line measured at 24 h increments. B: The critical
role of JNK-pathway activation was assessed in MDA-MB-231 cells by using the JNK inhibitor V (JNKi-V) as described in Figure 3E. C: IL-4 induces survivin up-regulation in
serum-depleted MDA-MB-231 cells. Analysis by Western blot showing the time course effect of IL-4 on survivin expression in breast cancer MDA-MB-231 cells treated as
described in (A). D: Proposed mechanism by which IL-4 induces cancer proliferation under nutrient-depletion stress. In the tumor microenvironment, cancer cells face a shortage
of nutrients that results in the down-regulation of survivin and a consequent decrease in proliferation. However, in this challenging and stressed environment, IL-4 turns on a
proliferation mechanism mediated by the simultaneous activation of the JNK-pathway and the up-regulation of survivin.
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stress-activated kinase, JNK, as a major pathway that mediates the
proliferation response induced by IL-4 in prostate cancer PC3 cells
under a nutrient-depletion stress (Fig. 3). However, neither ERK nor
p38 inhibition demonstrated a direct effect on cancer proliferation
(Fig. 3A–D). Supporting the importance of JNK is the fact that a
JNKi-V, which demonstrated speciﬁc inhibition of JNK phosphory-
lation (Fig. 3F), also showed suppression of IL-4-induced prolifera-
tion (Fig. 3E). The JNK-pathway is primarily activated by cytokines
and exposure to environmental-stress [Davis, 2000]. Studies of JNK-
signaling support the role of JNK in tumor development and
progression. For example, a role for JNK in tumorigenesis has been
reported in liver-cancer development, whereby p38a-deﬁciency
increased proliferation resulting from sustained activation of the
JNK-JUN-pathway [Hui et al., 2007]. In a recent report, it was
demonstrated that a growth-promoting function of the death-
receptor, CD95, is mediated by JNK-JUN-pathway [Chen et al.,
2010]. In contrast to studies that demonstrate the pro-oncogenic role
of JNK, the tumor-suppressor activity of JNK has been reported to be
associated with its pro-apoptotic function [Kennedy and Davis,
2003]. Therefore, JNK may play a context-dependent role in
tumorigenesis. Furthermore, the role of JNK in prostate cancer is of
particular importance because the tumor-suppressor PTEN, that is
frequently lost in this cancer, leads to Akt-activation and increased
JNK-activity both in cell-lines and in clinical prostate-cancer
samples [Vivanco et al., 2007]. As PTEN is frequently mutated in
cancer, the JNK-mediated proliferation induced by IL-4 could be
more accentuated in this particular context.
Next, it was further demonstrated that IL-4 induces survivin up-
regulation in nutrient-depleted PC3 cells (Fig. 4A). Survivin is one of
the nodal proteins differentially expressed in cancer and linked to
multiple signaling pathways essential for tumor-progression and
metastasis, including cell-division networks and cellular-stress
responses [Altieri, 2008]. Survivin up-regulation by IL-4 has been
reported in colon cancer stem cells [Di Stefano et al., 2010].
Under nutrient-depletion stress, the cell machinery forces the
down-regulation of survivin, and therefore, it was hypothesized that
up-regulation of survivin was crucial in the mechanism of IL-4-
induced proliferation. By using survivin-shRNAs, it was demon-
strated that the IL-4-induced prostate cancer cell proliferation was
dependent on survivin levels. In fact, as demonstrated in Figure 5,
IL-4-induced proliferation decreased substantially due to the
shRNA-mediated survivin knockdown in PC3. It was further
demonstrated that IL-4 induces a sustained activation of the
p70S6-kinase (Fig. 5D), a downstream target of mTORC1, which
have been demonstrated to enhance translation of survivin-
transcripts [Vaira et al., 2007] that correlates with an increase in
survivin protein (Fig. 5E, lines 5 and 7). Furthermore, by using JNKi-
V, it was further determined that the IL-4-induced survivin up-
regulation is independent of JNK-activation. Indeed, survivin levels
were not affected by the inhibitor concentration that demonstrated a
negative effect on cell proliferation (Fig. 5E, lines 7 and 8). These
ﬁndings suggest that survivin expression above a threshold limit in
a challenging nutrient-depleted environment is essential for cellular
proliferation, and therefore, IL-4-mediates PC3 cell-proliferation
through independent activation of JNK-signaling and up-regulation
of survivin.
Further understanding of how survivin up-regulation in a
nutrient-depleted environment contributes to cell proliferation
came from in vivo experiments in the ICI-model of prostate cancer
extravasation and metastasis using survivin-knockdown cells. In
these cells, survivin-shRNAs induce knockdown under depleted
nutrients; however, no differences in proliferation or survivin levels
were observed in vitro when they grow in the presence abundant
nutrients (Fig. 4B,C). When injected into mice, cancer cells in the
bloodstream spread throughout the body and seed into various
niches. This initial process of seeding and subsequent growth occurs
in an environment that is hostile to the cancer cells and that contains
a very limited supply of nutrients. Consequently, decreased survivin
under this environmental stress, as found in our knockdowns, would
obstruct this initial process of seeding and growth, essential for
tumor progression. In fact, as shown in Figure 6A,B, a signiﬁcant
difference in tumor progression and survival was observed between
mice injected with knockdown-cells compared to those injected with
control. Furthermore, tumors isolated from survivin-knockdown
cells demonstrated lower proliferation as evidenced by IHC-staining
with antibody for the proliferation marker Ki67 in correlation with
lower survivin staining (Fig. 6C).
Although the mechanism presented here is demonstrated in
prostate cancer PC3 cells, it was shown that under nutrient-
depletion stress, IL-4 could induce proliferation in cancer cells
from multiple origins: Breast, head and neck, and ovarian cancer
(Fig. 7A). Furthermore, the critical factors of this mechanism
identiﬁed in PC3 could have a general implication in other cancer
cells as suggested for breast cancer MDA-MB-231 (Fig. 7B,C).
Tumor metastases are characterized by high environmental-stress
and shortage of nutrients. The results presented here suggest that
survivin expression is up-regulated in this environment by IL-4, a
cytokine highly expressed by the leukocyte inﬁltrate found in the
tumor microenvironment [Gocheva et al., 2010; Gordon and
Martinez, 2010]. In this context, the up-regulation of survivin
above a necessary threshold limit is a pathological event, which
combined with JNK-hyperactivation, will guarantee tumor growth
even in the most adverse conditions (Fig. 7D). The goal to effectively
target survivin could be difﬁcult to achieve because according to the
ﬁndings presented here, survivin levels and cell proliferation could
be rescued by cytokines like IL-4 (Figs 4A and 5B,E). However, if the
most critical factors that contribute to survivin expression and JNK-
activation are identiﬁed in this milieu, a targeted-therapy against
them may represent an effective approach to halt tumor prolifera-
tion (Fig. 7D). Alternatively, simultaneous targeting of JNK and
survivin could be effective against metastatic tumors like prostate
cancer, characterized by PTEN deletion and high survivin
expression.
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